367 related articles for article (PubMed ID: 27791347)
1. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
3. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
[TBL] [Abstract][Full Text] [Related]
4. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
Yoshida H; Kimura A; Fukaya T; Sekiya T; Morita R; Shichita T; Inoue H; Yoshimura A
Biochem Biophys Res Commun; 2012 Feb; 418(2):234-40. PubMed ID: 22252297
[TBL] [Abstract][Full Text] [Related]
5. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
6. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis.
Shan S; Zhou Y; Yu J; Yang Q; Pan D; Wang Y; Li L; Zhu J; Zhang Y; Huang S; Li Z; Ning Z; Xin L; Lu X
Int Immunopharmacol; 2019 Dec; 77():105914. PubMed ID: 31634789
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
[TBL] [Abstract][Full Text] [Related]
9. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
12. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
13. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
[TBL] [Abstract][Full Text] [Related]
14. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Mohamed MF; Beck D; Camp HS; Othman AA
J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
[TBL] [Abstract][Full Text] [Related]
16. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Ghoreschi K; Jesson MI; Li X; Lee JL; Ghosh S; Alsup JW; Warner JD; Tanaka M; Steward-Tharp SM; Gadina M; Thomas CJ; Minnerly JC; Storer CE; LaBranche TP; Radi ZA; Dowty ME; Head RD; Meyer DM; Kishore N; O'Shea JJ
J Immunol; 2011 Apr; 186(7):4234-43. PubMed ID: 21383241
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.
Pei H; He L; Shao M; Yang Z; Ran Y; Li D; Zhou Y; Tang M; Wang T; Gong Y; Chen X; Yang S; Xiang M; Chen L
Sci Rep; 2018 Mar; 8(1):5273. PubMed ID: 29588471
[TBL] [Abstract][Full Text] [Related]
18. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
[TBL] [Abstract][Full Text] [Related]
19. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
[TBL] [Abstract][Full Text] [Related]
20. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.
De Vries LCS; Duarte JM; De Krijger M; Welting O; Van Hamersveld PHP; Van Leeuwen-Hilbers FWM; Moerland PD; Jongejan A; D'Haens GR; De Jonge WJ; Wildenberg ME
Inflamm Bowel Dis; 2019 Mar; 25(4):647-660. PubMed ID: 30668755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
